AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 12.3% in December

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,000,000 shares, a decrease of 12.3% from the November 30th total of 1,140,000 shares. Based on an average daily trading volume, of 582,000 shares, the short-interest ratio is presently 1.7 days.

AngioDynamics Stock Down 1.1 %

Shares of ANGO traded down $0.10 during trading on Friday, reaching $8.91. The company’s stock had a trading volume of 218,279 shares, compared to its average volume of 529,110. The company has a market cap of $362.05 million, a price-to-earnings ratio of -1.46 and a beta of 0.68. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $9.58. The company has a fifty day moving average of $7.56 and a two-hundred day moving average of $7.13.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The company had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.12) EPS. As a group, equities analysts forecast that AngioDynamics will post -0.41 EPS for the current fiscal year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average price of $6.03 per share, with a total value of $120,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. The trade was a 3.02 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders acquired 22,568 shares of company stock worth $135,847. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Segall Bryant & Hamill LLC grew its position in AngioDynamics by 142.7% in the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock worth $7,091,000 after acquiring an additional 535,958 shares in the last quarter. Millennium Management LLC grew its holdings in shares of AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock worth $10,850,000 after purchasing an additional 529,861 shares in the last quarter. Systematic Financial Management LP raised its stake in shares of AngioDynamics by 14.3% in the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock valued at $18,752,000 after buying an additional 300,785 shares in the last quarter. First Eagle Investment Management LLC bought a new position in AngioDynamics during the second quarter worth about $1,321,000. Finally, JPMorgan Chase & Co. boosted its position in AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock valued at $4,304,000 after buying an additional 123,271 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research note on Tuesday, December 10th. Canaccord Genuity Group dropped their target price on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.